Decision framework: Start existing treatments (semaglutide or tirzepatide) if: Your health risks from obesity are significant and immediate (uncontrolled diabetes, severe sleep apnea, cardiovascular disease) You have access to approved therapies through insurance or can afford them You need proven, FDA-approved medications with established safety profiles Waiting 1-2+ years for retatrutide approval doesnt align with your health timeline Consider waiting if: Youre currently at a stable weight with controlled health conditions Youve tried semaglutide or tirzepatide and hit a plateau but tolerated them well Youre in a position to potentially enroll in a retatrutide clinical trial You understand waiting means continued health risks from obesity Dont wait if: You think retatrutide will be a magic bullet with no downsides Your doctor is recommending treatment now for medical reasons Youre using waiting for the next best thing as an excuse to avoid addressing the problem The lifestyle component is non-negotiable regardless of which medication you use: High protein intake (0.7-1g per pound of body weight daily) to preserve muscle during weight loss
If youve shaken it vigorously, the integrity of the solution is likely compromised and it should not be used for accurate research
Then, shift your focus to the drug itself, making sure the pharmacy uses the correct active ingredient
Unopened GLP1 pens must stay refrigerated (36F to 46F)
In the STEP 1 semaglutide trial (Wilding et al., NEJM , 2021) and the SURMOUNT-1 tirzepatide trial (Jastreboff et al., NEJM , 2022), nausea affected roughly 44% of semaglutide patients and about 24% of tirzepatide patients at the maximum dose
How does retatrutide compare to tirzepatide and semaglutide
